Mckesson (MCK)

McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, its employees work every day to innovate and deliver opportunities that make our customers and partners more successful - all for the better health of patients. McKesson has been named a 'Most Admired Company' in the healthcare wholesaler category by FORTUNE, a 'Best Place to Work' by the Human Rights Campaign Foundation, and a top military-friendly company by Military Friendly.

Company profile

Brian Tyler
Fiscal year end
Former names
McKesson Europe AG • McKesson Europe Holdings GmbH • McKesson Global Procurement & Sourcing Limited • McKesson International • McKesson Ireland Limited • McKesson Medical-Surgical Holdings Inc. • McKesson Medical-Surgical Inc. • McKesson Medical-Surgical Top Holdings Inc. • McKesson Plasma and Biologics LLC • McKesson Specialty Care Distribution LLC ...
IRS number

MCK stock data


3 Aug 22
12 Aug 22
31 Mar 23
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Mar 22 Mar 21 Mar 20 Mar 19
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 2.34B 2.34B 2.34B 2.34B 2.34B 2.34B
Cash burn (monthly) 531.67M 16.25M (no burn) (no burn) 313.67M (no burn)
Cash used (since last report) 769.31M 23.51M n/a n/a 453.87M n/a
Cash remaining 1.57B 2.32B n/a n/a 1.89B n/a
Runway (months of cash) 3.0 142.6 n/a n/a 6.0 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
22 Jul 22 Richard H Carmona RSU Common Stock Grant Acquire A No No 0 606 0 606
22 Jul 22 Webster Roy Dunbar RSU Common Stock Grant Acquire A No No 0 606 0 606
22 Jul 22 James H. Hinton RSU Common Stock Grant Acquire A No No 0 606 0 606
22 Jul 22 Kathleen Wilson-Thompson RSU Common Stock Grant Acquire A No No 0 606 0 606
22 Jul 22 Linda Provie Mantia RSU Common Stock Grant Acquire A No No 0 606 0 606
89.1% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 1103 1063 +3.8%
Opened positions 149 192 -22.4%
Closed positions 109 66 +65.2%
Increased positions 345 349 -1.1%
Reduced positions 419 344 +21.8%
13F shares Current Prev Q Change
Total value 38.84B 31.96B +21.5%
Total shares 128.08M 129.05M -0.7%
Total puts 1.77M 1.08M +64.9%
Total calls 1.53M 1.43M +6.7%
Total put/call ratio 1.2 0.8 +54.6%
Largest owners Shares Value Change
Vanguard 15.44M $4.73B -0.4%
BLK Blackrock 11.57M $3.54B -12.2%
STT State Street 6.54M $2.01B -3.9%
JPM JPMorgan Chase & Co. 5.97M $1.83B +3.6%
Massachusetts Financial Services 5.63M $1.72B -1.3%
FMR 3.33M $1.02B -10.5%
BRK.A Berkshire Hathaway 2.92M $894.5M NEW
Geode Capital Management 2.86M $872.7M +1.2%
PZN Pzena Investment Management 2.7M $827.31M -8.4%
IVZ Invesco 2.53M $775.4M -14.9%
Largest transactions Shares Bought/sold Change
BRK.A Berkshire Hathaway 2.92M +2.92M NEW
BLK Blackrock 11.57M -1.61M -12.2%
Norges Bank 0 -1.56M EXIT
BCS Barclays 1.37M +992.08K +265.5%
Aaron Wealth Advisors 890.84K +887.92K +30460.5%
Acadian Asset Management 1.08M +843.35K +360.8%
Glenview Capital Management 936.04K -603.81K -39.2%
American Century Companies 992.39K -589.1K -37.2%
Marshall Wace 671.61K +522.58K +350.7%
Nordea Investment Management Ab 1.08M -446.72K -29.3%

Financial report summary

  • We experience costly and disruptive legal disputes.
  • We might experience losses not covered by insurance or indemnification.
  • We experience costly legal disputes, government actions, and adverse publicity regarding our role in distributing controlled substances such as opioids.
  • We might experience increased costs to distribute controlled substances such as opioids.
  • We are subject to extensive, complex and challenging healthcare and other laws.
  • We might lose our ability to purchase, compound, store or distribute pharmaceuticals and controlled substances.
  • Privacy and data protection laws increase our compliance burden.
  • Anti-bribery and anti-corruption laws increase our compliance burden.
  • We might record significant charges from impairment to goodwill, intangibles and other assets or investments.
  • We experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches.
  • We might experience significant problems with information systems or networks.
  • Our products or services might not conform to specifications or perform as we intend.
  • We might not realize expected benefits from business process initiatives.
  • We might be unable to successfully complete or integrate acquisitions or other business combinations.
  • Exclusive forum provisions in our Bylaws could limit our stockholders’ ability to choose their preferred judicial forum for disputes with us or our directors, officers or employees.
  • We might not realize the expected tax treatment from our split-off of Change Healthcare.
  • We might be adversely impacted by outsourcing or similar third-party relationships.
  • We may be unsuccessful in achieving our strategic growth objectives.
  • We might be harmed by large customer purchase reductions, payment defaults or contract non-renewal.
  • Our contracts with government entities involve future funding and compliance risks.
  • Our participation in vaccination distribution programs may materially affect our operating results, reputation, and business.
  • We might be harmed by changes in our relationships or contracts with suppliers.
  • We might infringe intellectual property rights or our intellectual property protections might be inadequate.
  • Our use of third-party data is subject to limitations that could impede the growth of our data services business.
  • We might be unable to successfully recruit and retain qualified employees.
  • We might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models.
  • We might be adversely impacted by competition and industry consolidation.
  • We might be adversely impacted by changes or disruptions in product supply.
  • We might be adversely impacted as a result of our distribution of generic pharmaceuticals.
  • We might be adversely impacted by inflation, an economic slowdown, or recession.
  • Disruption or other changes in capital and credit markets might impede access to credit and increase borrowing costs for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers.
  • We may have difficulties in sourcing or selling products due to a variety of causes.
  • We might be adversely impacted by tax legislation or challenges to our tax positions.
  • We might be adversely impacted by fluctuations in foreign currency exchange rates.
  • We might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events, and other catastrophic events.
  • We may be adversely affected by global climate change or by legal, regulatory, or market responses to such change.
  • We might be adversely impacted by changes in accounting standards.
Management Discussion
  • Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.
  • Management’s discussion and analysis of financial condition and results of operations, referred to as the “Financial Review,” is intended to assist the reader in the understanding and assessment of significant changes and trends related to the results of operations and financial position of McKesson Corporation together with its subsidiaries (collectively, the “Company,” “McKesson,” “we,” “our,” or “us” and other similar pronouns). This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying financial notes in Item 1 of Part I of this Quarterly Report on Form 10-Q (“Quarterly Report”) and in Item 8 of Part II of our Annual Report on Form 10-K for the fiscal year ended March 31, 2022 previously filed with the Securities and Exchange Commission on May 9, 2022 (“2022 Annual Report”).
  • Our fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean our fiscal year.

Content analysis

H.S. sophomore Avg
New words: adequately, admit, analytical, assumed, avoid, binding, burden, chose, circumstance, colluding, commodity, conflict, created, dedicated, deemed, delay, Denmark, derecognized, difficult, disgorgement, diversified, divested, entry, failed, Fewer, Hart, hindsight, Holdco, impracticable, improved, inability, independent, innovative, knowingly, length, liable, lifecycle, lock, mentioned, military, minimize, mistrial, NG, objectively, Omni, preferable, principle, prohibit, purported, quality, release, released, Reliable, repackaged, restrain, retrospective, Russia, school, separate, Sherman, show, small, subdivision, talent, temperature, therapeutic, Ukraine, unrest, unsealing, voluntarily, waive, War, willfully, wrongdoing
Removed: abstinence, acquisition, adequacy, administered, Administration, aforementioned, agree, Amendment, applying, appraisal, arrangement, assembled, awarded, borrowed, bound, broader, calculate, calculating, cancelled, captioned, cease, charitable, children, combining, commencing, commitment, community, comparing, conclude, consolidating, converting, death, decommissioning, deferred, deposit, direct, disbursed, discounted, dismissal, dismissed, domestic, donate, donation, drove, duration, Emergency, employee, enhanced, enter, enterprise, environment, estate, EURIBOR, exact, exceeded, expert, expiration, extinguishment, face, finalized, Food, foot, foreclose, foreclosed, full, FX, GmbH, hand, headcount, implemented, incur, infected, inflated, inflow, initially, initiated, insurance, intraperiod, Island, KGaA, largest, lesser, list, manufactured, mature, medical, methodology, Nassau, navigation, negatively, neonatal, November, obsolete, offer, Ohio, onset, Opiate, originally, outcome, owed, packing, patient, pendency, Pfizer, picking, pickup, playing, preparing, present, proportion, proportional, putative, qualified, qualitative, quantitative, rapidly, real, realignment, recognition, recommended, recovery, redeem, redeemed, reducing, reduction, reflecting, Regional, registration, rejecting, relate, RelayHealth, remained, reorganizing, repurpose, requiring, resale, resulted, retain, retired, return, Rhode, ruled, safely, safety, scheduled, seasonality, segregation, Simplifying, situation, strain, Stuttgart, subsequently, Suffolk, superseded, supported, supporting, swap, syndrome, telecommuting, temporarily, tender, thereto, traffic, travel, unadjusted, unaffiliated, unamortized, uncertain, unfavorably, utero, vi, vii, viral, warrant, WBA, weakened, worked, workplace, written, wrongful